The immunogenicity of biological drugs can usually induce the body to produce immune responses to them and produce anti-drug antibodies.The CAR structure on the surface of CAR-T cells is not a receptor normally expressed on the surface of human T cells, and it is possible for the body to generate anti-drug antibodies to CAR-T cells during use. Therefore, the immunogenicity of CAR-T cell drugs needs to be evaluated during drug development and treatment.
Anti-drug antibodies generally fall into two categories: neutralizing and nonneutralizing. Non-neutralizing antibodies bind to the inactive sites of CAR-T cells and do not directly affect drug activity. The neutralizing antibody directly binds to the active site of CAR-T cells and prevents or reduces the binding of CAR-T cells to tumor surface targets, exerting a great influence on drug efficacy.
Catalog | product | Specification |
---|---|---|
200120 | Rabbit Anti-Mouse FMC63 scFv Monoclonal Antibody | 1mg/mL, 100 μg |
500019 | Rabbit Anti-Mouse FMC63 scFv Polyclonal Antibody | 1mg/mL, 100 μg |